We only have this paper's title and publication details.
Read it at the sourceThese results further support blinatumomab as a treatment option for patients with r/r Ph+ ALL.
No takes yet. Share an insight, caveat, or question.
Rambaldi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: